

Heterocyclic compounds as autotaxin inhibitors

BACKGROUND OF THE INVENTION

- 5 The invention was based on the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.
- 10 The present invention relates to compounds and to the use of compounds for the treatment of diseases which are accompanied by an increase in the lysophosphatidic acid level, furthermore to pharmaceutical compositions which comprise these compounds.
- 15 In detail, the present invention relates to compounds of the formula I, which preferably inhibit one or more enzymes which regulate and/or modulate the lysophosphatidic acid (or LPA for short) level, to compositions which comprise these compounds, and to processes for the use thereof for the treatment of diseases and complaints, such as angiogenesis, cancer, tumour
- 20 formation, growth and propagation, arteriosclerosis, ocular diseases, choroidal neovascularisation and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing or transplant rejection. In particular, the compounds according to the invention are suitable for the therapy or prophylaxis of cancer diseases.
- 25
- 30 Autotaxin (ATX) is an enzyme which is responsible for the increase in the lysophosphatidic acid level in ascites and plasma (Xu et al. 1995, Clinical Cancer Research Vol. 1, page 1223 and Xu et al. 1995, Biochem. J. Vol-309, page 933). ATX converts lysophatidylcholine (LPC) into lysophosphatidic acid (Tokumura et al. 2002, J. Biol. Chem., Vol 277, page 39436 and Umezū-Gozo et al. 2002, J. Biol. Chem., Vol. 277, page 227) LPA is an
- 35 intercellular lipid mediator which influences a multiplicity of biological and biochemical processes, such as, for example, smooth muscle contraction,

thrombocyte aggregation and apoptosis (Tigyi et al. 2003 Prog. Lipid Res. Vol 42 , page. 498 and Mills et al. 2003 Nat. Rev. Cancer Vol. 3, page 582 and Lynch et al. 2001 Prost. Lipid Med. Vol.64, page 33). In addition, LPA can be found in increased concentrations in plasma and ascites fluid from ovarian cancer patients in the early and late phase. LPA plays a role there in tumour cell proliferation and invasion thereof into neighbouring tissue, which can result in metastatisation (Xu et al. 1995, Clinical Cancer Research Vol. 1, page 1223 and Xu et al. 1995, Biochem. J. Vol- 309, page 933). These biological and phatobiological processes are switched on by the activation by LPA of G-protein-coupled receptors (Contos et al. 2000, Mol. Pharm. Vol 58, page. 1188).

For this reason, it is desirable to lower the LPA level for the treatment of tumour patients. This can be achieved by the inhibition of enzymes which are involved in LPA biosynthesis, such as, for example, autotaxin (ATX, Sano et al. 2002, J. Biol. Chem. Vol. 277 , page 21197 and Aoki et al. 2003, J. Biol. Chem. Vol. 277 page 48737). Autotaxin belongs to the enzyme family of the nucleotides pyrophosphatases and phosphodiesterases (Goding et al. 1998, Immunol. Rev. Vol. 161, page 11) and represents an important starting point in antitumour therapy (Mills et al. 2003 Nat. Rev. Cancer Vol. 3, page 582 and Goto eta l. 2004 J. Cell. Biochem. Vol. 92, page 1115) since it is expressed to an increased extent in tumours and causes tumour cell proliferation and invasion into neighbouring tissue, which can result in metastases formation (Ivam et al. 2000, Oncogene, Vol. 19 page 241). In addition, autotaxin together with other angiogenetic factors causes blood vessel formation in the course of angiogenesis (Nam et al. 2001, Cancer Res. Vol. 61 page. 6938). Angiogenesis is an important process in tumour growth, which ensures supply of the tumour with nutrients. For this reason, inhibition of angiogenesis is an important starting point in cancer and tumour therapy, with which the tumour can be starved to a cer-

tain extent (Folkman, 2007, Nature Reviews Drug Discovery Vol. 6, page 273-286).

5 Surprisingly, it has been found that the compounds according to the invention cause specific inhibition of the enzyme family of the nucleotides pyrophosphatases and phosphodiesterases, in particular autotaxin. The compounds according to the invention preferably exhibit an advantageous biological activity, which can easily be detected in the test described, for example, herein. In tests of this type, the compounds according to the invention preferably exhibit and cause an inhibiting effect, which is usually documented by IC_{50} values in a suitable range, preferably in the micromolar range and more preferably in the nanomolar range.

15 In general, all solid and non-solid tumours can be treated with the compounds of the formula I, such as, for example, monocytic leukaemia, brain, urogenital, lymphatic system, stomach, laryngeal, ovarian and lung carcinoma, including lung adenocarcinoma and small-cell lung carcinoma. Further examples include prostate, pancreatic and breast carcinoma.

25 As discussed herein, effects of the compound according to the invention are relevant for various diseases. Accordingly, the compounds according to the invention are useful in the prophylaxis and/or treatment of diseases which are influenced by inhibition of one or more nucleotides pyrophosphatases and/or phosphodiesterases, in particular autotaxin.

30 The present invention therefore relates to compounds according to the invention as medicaments and/or medicament active ingredients in the treatment and/or prophylaxis of the said diseases and to the use of compounds according to the invention for the preparation of a pharmaceutical agent for the treatment and/or prophylaxis of the said diseases, and also to
35 a method for the treatment of the said diseases comprising the administra-

tion of one or more compounds according to the invention to a patient in need of such administration.

5 It can be shown that the compounds according to the invention have an advantageous action in a xenotransplant tumour model.

10 The host or patient can belong to any mammalian species, for example a primate species, in particular humans; rodents, including mice, rats and hamsters; rabbits; horses, cattle, dogs, cats, etc. Animal models are of interest for experimental investigations, where they provide a model for the treatment of a human disease.

15 The sensitivity of a certain cell to treatment with the compounds according to the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound according to the invention at various concentrations for a time which is sufficient to enable the active agents to induce cell death or to inhibit cell migration or to block the cellular secretion of angiogenesis-promoting substances, usually between approximately one
20 hour and one week. For testing in vitro, cultivated cells from a biopsy sample can be used. The viable cells remaining after the treatment are then counted.

25 The dose varies depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose is sufficient to considerably reduce the undesired cell population in the target tissue, while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example at least about
30 a 50% reduction in the cell burden, and can be continued until essentially no undesired cells can be detected in the body.


35

PRIOR ART

Compounds which are capable of inhibiting autotaxin are described in Peng et al. Bioorganic & Medicinal Chemistry Letters (17, 2007, page 1634-1640). The compounds described therein are lipid analogues, which do not have any structural features in common with the compounds according to the invention.

SUMMARY OF THE INVENTION

The invention relates to compounds of the formula I



in which


R^1 denotes H, A, Hal, OR^3 , $\text{N}(\text{R}^3)_2$, $\text{N}=\text{CR}^3\text{N}(\text{R}^3)_2$, SR^3 , NO_2 , CN, COOR^3 , $\text{CON}(\text{R}^3)_2$, NR^3COA , $\text{NR}^3\text{SO}_2\text{A}$, $\text{SO}_2\text{N}(\text{R}^3)_2$, $\text{S}(\text{O})_m\text{A}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{N}(\text{R}^3)_2$, $\text{O[}(\text{C}(\text{R}^3)_2\text{)]}_p\text{N}(\text{R}^3)_2$, $\text{S[}(\text{C}(\text{R}^3)_2\text{)]}_n\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{[}(\text{C}(\text{R}^3)_2\text{)]}_n\text{N}(\text{R}^3)_2$, $\text{NHCON}(\text{R}^3)_2$, $\text{CON}(\text{R}^3)_2$, $\text{CONR}^3\text{[}(\text{C}(\text{R}^3)_2\text{)]}_n\text{N}(\text{R}^3)_2$ or COA,

R^3 denotes H or A,

X denotes O, NH or CH_2 ,


Y denotes CH_2 , CH_2O or is absent,

R denotes



R^4 denotes H, A or phenyl,

Het denotes



10 A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one or two CH₂ groups may be replaced by O, NH and/or S,

15 or
cyclic alkyl having 3-7 C atoms,

Hal denotes F, Cl, Br or I.

n denotes 0, 1, 2 or 3,

m denotes 0, 1 or 2.

²⁰ p denotes 0, 1, 2, 3, 4 or 5.

and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

25 Compounds of the formula I also mean pharmaceutically usable derivatives thereof, optically active forms (stereoisomers), tautomers, polymorphs, enantiomers, racemates, diastereomers and the hydrates and solvates of these compounds. The term solvates of the compounds is taken to mean
30 adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. solvates are, for example, mono- or dihydrates or alcoholates.

35 Pharmaceutically usable derivatives are taken to mean, for example, the salts of the compounds according to the invention and also so-called pro-drug compounds.

Prodrug derivatives are taken to mean compounds of the formula I which have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention.

These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995).

The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.

In addition, the expression "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence: improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side effects or also the reduction in the advance of a disease, complaint or disorder.


The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function.

The invention also relates to the use of mixtures of the compounds of the formula I, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.

These are particularly preferably mixtures of stereoisomeric compounds.


The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I according to the patent claims and pharmaceutically usable salts, and stereoisomers thereof, characterised in that

a) for the preparation of compounds of the formula I in which



5

a compound of the formula II




10

in which

Het has the meaning indicated in Claim 1,
and L denotes Cl or Br,

is reacted with a compound of the formula III

15



20


in which

X, Y, R¹ and p have the meanings indicated in Claim 1,

25


or

b) for the preparation of compounds of the formula I in which



30

a compound of the formula IV



35


in which

Het has the meaning indicated in Claim 1,

and L denotes Cl or Br,

5

is reacted with a compound of the formula V



10

in which


X, Y, R¹ and p have the meanings indicated in Claim 1,

15

or

c) for the preparation of compounds of the formula I in which

20



25

a compound of the formula VI



in which

30

Het has the meaning indicated in Claim 1,


and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

35


is reacted with a compound of the formula V,

or

d) for the preparation of compounds of the formula I in which




10 a compound of the formula VII



in which

Het has the meaning indicated in Claim 1,

20 is reacted with a compound of the formula VIII



in which

30 R^1 and p have the meanings indicated in Claim 1,

and a compound selected from the group
carbonyldiimidazole, phosgene, diphosgene, triphosgene,

35 or


12

e) for the preparation of compounds of the formula I in which

R denotes



a compound of the formula IX




in which

Het has the meaning indicated in Claim 1,


is reacted with a compound of the formula V
and a compound selected from the group
carbonyldiimidazole, phosgene, diphosgene, triphosgene,

or

f) for the preparation of compounds of the formula I in which




a compound of the formula X



in which

Het has the meaning indicated in Claim 1,

is reacted with a compound of the formula XI



in which

10 X, Y, R¹, p have the meanings indicated in Claim 1,
and L denotes Cl, Br, I or a free or reactively functionally
modified OH group,

15 and/or a base or acid of the formula I is converted into one of its salts.

20 A denotes alkyl and is preferably unbranched (linear) or branched, and has
1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. Alkyl preferably denotes methyl, fur-
thermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, fur-
thermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethyl-
propyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-,
2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl,
1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, further preferably, for
25 example, trifluoromethyl.

Alkyl very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C
atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,
tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoro-
ethyl. Alkyl also denotes cycloalkyl.

30 Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl
or cycloheptyl.

Hal preferably denotes F, Cl or Br, but also I, particularly preferably Br or Cl.

35 R¹ preferably denotes Hal.

R^3 preferably denotes H or methyl.

X preferably denotes O or CH_2 .

Y preferably denotes CH_2 or CH_2O .

p preferably denotes 1, 2 or 3, furthermore 4 or 5.

n preferably denotes 0, 1, 2 or 3.

Throughout the invention, all radicals which occur more than once, such as, for example, R, may be identical or different, i.e. are independent of one another.

The compounds of the formula I may have one or more chiral centres and can therefore occur in various stereoisomeric forms. The formula I encompasses all these forms.

Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above.

Some preferred groups of compounds may be expressed by the following sub-formulae Ia to Ie, which conform to the formula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which


in Ia R^1 denotes Hal;

in Ib X denotes O or CH_2 ;

in Ic Y denotes CH_2 or CH_2O ;

in Id p denotes 1, 2 or 3;

in Ie R^1 denotes Hal,
X denotes O or CH_2 ,



- A denotes unbranched or branched alkyl having 1-10 C atoms,
in which 1-7 H atoms may be replaced F and/or Cl,
Hal denotes F, Cl, Br or I,
p denotes 1, 2 or 3,

and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se which are not mentioned here in greater detail.

The starting materials can, if desired, also be formed in situ by not isolating them from the reaction mixture, but instead immediately converting them further into the compounds of the formula I.

The starting compounds of the formulae II, III, IV, V, VI, VII, VIII, IX, X and XI are generally known. If they are novel, however, they can be prepared by methods known per se.

The starting materials are generally also commercially available.

In the compounds of the formula II, IV, VI, XI, L preferably denotes Cl, Br, I or a free or a reactively modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

Compounds of the formula I can preferably be obtained by reacting a compound of the formula II with a compound of the formula III.

The reaction is generally carried out in an inert solvent, in the presence of an acid-binding agent preferably an alkali or alkaline-earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline-earth metals, preferably of potassium, sodium, calcium or caesium. The addition of an organic base, such as triethylamine, dimethylaniline, pyridine or quinoline, may also be favourable.

Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 140°, normally between -10° and 90°, in particular between about 0° and about 70°, very particularly preferably between 15 and 35°C.

Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disul-

fide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.

Particular preference is given to pyridine, acetonitrile, dichloromethane and/or DMF.

Compounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula IV with a compound of the formula V under conditions as described above.

The reaction is preferably carried out in acetonitrile at 100°C with addition of NaHCO_3 .

Compounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula VI with a compound of the formula V. In the compounds of the formula VI, L preferably denotes OH. For the reaction, the carboxyl group is preferably converted into an active ester.

Radicals of this type for activation of the carboxyl group in typical acylation reactions are described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart;).

Activated esters are advantageously formed in situ, for example by addition of HOBt or N-hydroxysuccinimide.

The reaction preferably succeeds in the presence of a dehydrating agent, such as, for example, a carbodiimide, such as N,N'-dicyclohexylcarbodiimide ("DCCI"), 1,1'-carbonyldiimidazole (CDI) or N-3-dimethylaminopropyl-N'-ethylcarbodiimide ("DAPECI"), furthermore propanephosphonic anhydride (cf. Angew. Chem. 92, 129 (1980)), diphenylphosphoryl azide or 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline.

The reaction is generally carried out in an inert solvent.

Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -15° and 150°, normally between -5° and 90°, particularly preferably between 20° and 60°C.

The reaction is preferably carried out in DMF at room temperature and preferably with addition of N-methylmorpholine.

Compounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula VII with a compound of the formula VIII and a compound selected from the group carbonyldiimidazole, phosgene, diphosgene, triphosgene.

The reaction is carried out in an inert solvent and under conditions as described above. The reaction is preferably carried out in DMF at room temperature and with addition of a carbonyl component, such as CDI.

Compounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula IX with a compound of the formula V and a compound selected from the group carbonyldiimidazole, phosgene, diphosgene, triphosgene.

The reaction is carried out in an inert solvent and under conditions as described above. The reaction is preferably carried out in DMF at room temperature and with addition of a carbonyl component, such as CDI, and a base, such as triethylamine.

Compounds of the formula I can furthermore preferably be obtained by reacting a compound of the formula VX with a compound of the formula XI.

The reaction is preferably carried out under conditions like the reaction of the compound of the formula VI with a compound of the formula V.

The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids

and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline-earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of the compounds of the formula I are likewise included. In the case of certain compounds of the formula I, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalene-

sulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction.

5 Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-men-
10 tioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline-earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, sec-
15 ondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chlorprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanol-
20 amine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperi-
25 dine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris(hydroxymethyl)-methylamine (tromethamine), but this is not intended to represent a restric-
tion.

30 Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C₁-C₄)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C₁-C₄)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C₁₀-C₁₈)alkyl halides, for example decyl, dodecyl, lauryl, myristyl
35 and stearyl chloride, bromide and iodide; and aryl(C₁-C₄)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-solu-

ble compounds according to the invention can be prepared using such salts.

5 The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and trometh-
10 amine, but this is not intended to represent a restriction.

The acid-addition salts of basic compounds of the formula I are prepared by bringing the free base form into contact with a sufficient amount of the
15 desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in
20 polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

As mentioned, the pharmaceutically acceptable base-addition salts of the
25 compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline-earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine,
30 ethylenediamine, N-methyl-D-glucamine and procaine.

The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount
35 of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner.

The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.

With regard to that stated above, it can be seen that the expression "pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably

1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.

Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).

Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for

example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

5 Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser,
10 such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medication after the capsule has been taken.

15 In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate,
20 carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto,
25 starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by
30 mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such
35 as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example,

5 syrup, starch paste, acacia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape, which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

20 Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

30 The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.

The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyranes, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).

Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.

Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.

Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.

Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

5 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxi-
dants, buffers, bacteriostatics and solutes, by means of which the formula-
tion is rendered isotonic with the blood of the recipient to be treated; and
10 aqueous and non-aqueous sterile suspensions, which may comprise sus-
pension media and thickeners. The formulations can be administered in
single-dose or multidose containers, for example sealed ampoules and
vials, and stored in freeze-dried (lyophilised) state, so that only the addition
15 of the sterile carrier liquid, for example water for injection purposes, imme-
diately before use is necessary. Injection solutions and suspensions pre-
pared in accordance with the recipe can be prepared from sterile powders,
granules and tablets.

20 It goes without saying that, in addition to the above particularly mentioned
constituents, the formulations may also comprise other agents usual in the
art with respect to the particular type of formulation; thus, for example, for-
mulations which are suitable for oral administration may comprise flavours.

25 A therapeutically effective amount of a compound of the formula I depends
on a number of factors, including, for example, the age and weight of the
animal, the precise condition that requires treatment, and its severity, the
30 nature of the formulation and the method of administration, and is ultimately
determined by the treating doctor or vet. However, an effective amount of a
compound according to the invention for the treatment of neoplastic growth,
for example colon or breast carcinoma, is generally in the range from 0.1 to
100 mg/kg of body weight of the recipient (mammal) per day and particu-
35 larly typically in the range from 1 to 10 mg/kg of body weight per day. Thus,
the actual amount per day for an adult mammal weighing 70 kg is usually

between 70 and 700 mg, where this amount can be administered as a single dose per day or more usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention *per se*. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

The invention also relates to a set (kit) consisting of separate packs of

- (a) an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
- (b) an effective amount of a further medicament active ingredient.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each containing an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.

The medicaments from Table 1 are preferably, but not exclusively, combined with the compounds of the formula I. A combination of the formula I and medicaments from Table I can also be combined with compounds of the formula VI.

Table 1.		
Alkylating agents	Cyclophosphamide Busulfan Ifosfamide Melphalan Hexamethylmelamine Thiotepa chloroambucil Dacarbazine Carmustine	Lomustine Procarbazine Altretamine Estramustine phosphate Mechloroethamine Streptozocin Temozolomide Semustine
Platinum agents	Cisplatin Oxaliplatin Spiroplatin Carboxyphthalatoplatinum Tetraplatin Orniplatin Iproplatin	Carboplatin ZD-0473 (AnorMED) Lobaplatin (Aetema) Satraplatin (Johnson Matthey) BBR-3464 (Hoffmann-La Roche) SM-11355 (Sumitomo) AP-5280 (Access)
Antimetabolites	Azacytidine Gemcitabine Capecitabine 5-fluorouracil Floxuridine 2-chlorodesoxyadenosine 6-Mercaptopurine 6-Thioguanine Cytarabine 2-fluorodesoxycytidine Methotrexate Idatrexate	Tomudex Trimetrexate Deoxycoformycin Fludarabine Pentostatin Raltitrexed Hydroxyurea Decitabine (SuperGen) Clofarabine (Bioenvision) Irofulven (MGI Pharma) DMDC (Hoffmann-La Roche) Ethynylcytidine (Taiho)
Topoisomerase inhibitors	Amsacrine Epirubicin Etoposide Teniposide or mitoxantrone Irinotecan (CPT-11) 7-Ethyl-10-hydroxycamptothecin Topotecan Dexrazoxanet (TopoTarget) Pixantrone (Novuspharma)	Rubitecan (SuperGen) Exatecan mesylate (Daiichi) Quinamed (ChemGenex) Gimatecan (Sigma- Tau) Diflomotecan (Beaufour- Ipsen) TAS-103 (Taiho) Elsamitrucin (Spectrum) J-107088 (Merck & Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun

	Rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharmna)	Dang) KW-2170 (Kyowa Hakko)
5	Antitumour antibiotics	Dactinomycin (Actinomycin D) Doxorubicin (Adriamycin) Deoxyrubicin Valrubicin Daunorubicin (Daunomycin) Epirubicin Therarubicin Idarubicin Rubidazone Plicamycinp Porfiromycin Cyanomorpholinodoxorubici Mitoxantrone (Novantrone)
10		Amonafide Azonafide Anthrapyrazole Oxantrazole Losoantrone Bleomycin sulfate (Blenoxan) Bleomycinic acid Bleomycin A Bleomycin B Mitomycin C MEN-10755 (Menarini) GPX-100 (Gem Pharmaceuticals)
15		
20	Antimitotic agents	Paclitaxel Docetaxel Colchicine Vinblastine Vincristine Vinorelbine Vindesine Dolastatin 10 (NCI) Rhizoxin (Fujisawa) Mivobulin (Warner- Lambert) Cemadotin (BASF) RPR 109881A (Aventis) TXD 258 (Aventis) Epothilone B (Novartis) T 900607 (Tularik) T 138067 (Tularik) Cryptophycin 52 (Eli Lilly) Vinflunine (Fabre) Auristatin PE (Teikoku hormone) BMS 247550 (BMS) BMS 184476 (BMS) BMS 188797 (BMS) Taxoprexin (Protarga)
25		SB 408075 (GlaxoSmithKline) E7010 (Abbott) PG-TXL (Cell Therapeutics) IDN 5109 (Bayer) A 105972 (Abbott) A 204197 (Abbott) LU 223651 (BASF) D 24851 (ASTA Medica) ER-86526 (Eisai) Combretastatin A4 (BMS) Isohomohalichondrin-B (PharmaMar) ZD 6126 (AstraZeneca) PEG-Paclitaxel (Enzon) AZ10992 (Asahi) !DN-5109 (Indena) AVLB (Prescient NeuroPharma) Azaepothilon B (BMS) BNP- 7787 (BioNumerik) CA-4-prodrug (OXiGENE) Dolastatin-10 (NrH) CA-4 (OXiGENE)
30		
35		
	Aromatase	Aminoglutethimide Exemestan

	inhibitors	Letrozole Anastrozole Formestan	Atamestan (BioMedicines) YM-511 (Yamanouchi)
5	Thymidylate syn- thase inhibitors	Pemetrexed (Eli Lilly) ZD-9331 (BTG)	Nolatrexed (Eximias) CoFactor™ (BioKeys)
10	DNA antagonists	Trabectedin (PharmaMar) Glufosfamide (Baxter International) Albumin + 32P (Isotope Solutions) Thymectacin (NewBiotics) Edotreotid (Novartis)	Mafosfamide (Baxter International) Apaziquone (Spectrum Pharmaceuticals) O6-benzylguanine (Paligent)
15	Farnesyl transferase inhibitors	Arglabin (NuOncology Labs) Tipifarnib (Johnson & lonafarnib (Schering-Plough Johnson) BAY-43-9006 (Bayer)	Perillyl alcohol (DOR BioPharma)
20	Pump inhibitors	CBT-1 (CBA Pharma) Tariquidar (Xenova) MS-209 (Schering AG)	Zosuquidar trihydrochloride (Eli Lilly) Biricodar dicitrate (Vertex)
25	Histone acetyl transferase in- hibitors	Tacedinaline (Pfizer) SAHA (Aton Pharma) MS-275 (Schering AG)	Pivaloyloxymethyl butyrate (Titan) Depsipeptide (Fujisawa)
30	Metalloproteinase inhibitors Ribonucleoside reductase inhibi- tors	Neovastat (Aeterna Labo- ratories) Marimastat (British Bio- tech) Gallium maltolate (Titan) Triapin (Vion)	CMT -3 (CollaGenex) BMS-275291 (Celltech) Tezacitabine (Aventis) Didox (Molecules for Health)
35	TNF-alpha agonists/ antagonists	Virulizin (Lorus Therapeutics) CDC-394 (Celgene)	Revimid (Celgene)
	Endothelin-A receptor antagonists	Atrasentan (Abbot) ZD-4054 (AstraZeneca)	YM-598 (Yamanouchi)
	Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson) LGD-1550 (Ligand)	Alitretinoin (Ligand)

Immunomodulators	Interferon Oncophage (Antigenics) GMK (Progenics) Adenocarcinoma vaccine (Biomira) CTP-37 (AVI BioPharma) JRX-2 (Immuno-Rx) PEP-005 (Peplin Biotech) Synchrovax vaccines (CTL Immuno) Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVax)	Dexosome therapy (Anosys) Pentrix (Australian Cancer Technology) JSF-154 (Tragen) Cancer vaccine (Intercell) Norelin (Biostar) BLP-25 (Biomira) MGV (Progenics) 13-Alethin (Dovetail) CLL-Thera (Vasogen)
Hormonal and antihormonal agents	Oestrogens Conjugated oestrogens Ethynyloestradiol chlorotrianisene Idenestrol Hydroxyprogesterone capro. Medroxyprogesterone Testosterone Testosterone propionate Fluoxymesterone Methyltestosterone Diethylstilbestrol Megestrol Tamoxifen Toremofin Dexamethasone	Prednisone Methylprednisolone Prednisolone Aminoglutethimide Leuprolide Goserelin Leuporelin Bicalutamide Flutamide Octreotide Nilutamide Mitotan P-04 (Novogen) 2-Methoxyoestradiol (EntreMed) Arzoxifen (Eli Lilly)
Photodynamic agents	Talaporfin (Light Sciences) Theralux (Theratechnologies) Motexafin gadolinium (Pharmacyclics)	Pd-bacteriopheophorbide (Yeda) Lutetium texaphyrin (Pharmacyclics) Hypericin
Tyrosine kinase inhibitors	Imatinib (Novartis) Leflunomide (Sugen/Pharmacia) ZDI839 (AstraZeneca) Erlotinib (Oncogene Sciences) Canertinib (Pfizer) Squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia)	Kahalide F (PharmaMar) CEP- 701 (Cephalon) CEP-751 (Cephalon) MLN518 (Millenium) PKC412 (Novartis) Phenoxodiol O Trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech)

5

10

15

20

25

30

35

	ZD4190 (AstraZeneca)	MDX-H210 (Medarex)
	ZD6474 (AstraZeneca)	2C4 (Genentech)
	Vatalanib (Novartis)	MDX-447 (Medarex)
	PKI166 (Novartis)	ABX-EGF (Abgenix)
	GW2016 (GlaxoSmithKline)	IMC-1C11 (ImClone)
	EKB-509 (Wyeth)	
	EKB-569 (Wyeth)	
Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo)	BCX-1777 (PNP inhibitor, BioCryst)
	Tocladesine (cyclic AMP agonist, Ribapharm)	Ranpirnase (ribonuclease stimulant, Alfacell)
	Alvocidib (CDK inhibitor, Aventis)	Galarubicin (RNA synthesis inhibitor, Dong-A)
	CV-247 (COX-2 inhibitor, Ivy Medical)	Tirapazamine (reducing agent, SRI International)
	P54 (COX-2 inhibitor, Phytopharm)	N-Acetylcysteine (reducing agent, Zambon)
	CapCell™ (CYP450 stimulant, Bavarian Nordic)	R-Flurbiprofen (NF-kappaB inhibitor, Encore)
	GCS-100 (gal3 antagonist, GlycoGenesys)	3CPA (NF-kappaB inhibitor, Active Biotech)
	G17DT immunogen (gastrin inhibitor, Aphton)	Seocalcitol (vitamin D receptor agonist, Leo)
	Efaproxiral (oxygenator, Allos Therapeutics)	131-I-TM-601 (DNA antagonist, TransMolecular)
	PI-88 (heparanase inhibitor, Progen)	Eflornithin (ODC inhibitor, ILEX Oncology)
	Tesmilifen (histamine antagonist, YM BioSciences)	Minodronic acid (osteoclast inhibitor, Yamanouchi)
	Histamine (histamine H2 receptor agonist, Maxim)	
	Tiazofurin (IMPDH inhibitor, Ribapharm)	Indisulam (p53 stimulant, Eisai)
	Cilengitide (integrin antagonist, Merck KGaA)	Aplidin (PPT inhibitor, PharmaMar)
	SR-31747 (IL-1 antagonist, Sanofi-Synthelabo)	Rituximab (CD20 antibody, Genentech)
	CCI-779 (mTOR kinase inhibitor, Wyeth)	Gemtuzumab (CD33 antibody, Wyeth Ayerst)
	Exisulind (PDE-V inhibitor, Cell Pathways)	PG2 (haematopoiesis promoter, Pharmagenesis)
	CP-461 (PDE-V inhibitor, Cell Pathways)	Immunol™ (triclosan mouthwash, Endo)
	AG-2037 (GART inhibitor, Pfizer)	Triacetyluridine (uridine prodrug, Wellstat)
	WX-UK1 (plasminogen activator-	SN-4071 (sarcoma agent, Signature BioScience)

5

10

15

20

25

30

35

	inhibitor, Wilex) PBI-1402 (PMN stimulant, ProMetic LifeSciences) Bortezomib (proteasome inhibitor, Millennium) SRL-172 (T-cell stimulant, SR Pharma) TLK-286 (glutathione-S transferase inhibitor, Telik) PT-100 (growth factor agonist, Point Therapeutics) Midostaurin (PKC inhibitor, Novartis) Bryostatins-1 (PKC stimulant GPC Biotech) CDA-II (apoptosis promoter, Everlife) SDX-101 (apoptosis promoter, Salmedix) Ceflatonin (apoptosis promoter, ChemGenex)	TransMID-107™ (immunotoxin, KS Biomedix) PCK-3145 (apoptosis promoter, Procyon) Doranidazole (apoptosis promoter, Pola) CHS-828 (cytotoxic agent, Leo) trans-Retinoic acid (differentiator, NIH) MX6 (apoptosis promoter, MAXIA) Apomine (apoptosis promot ILEX Oncology) Urocidin (apoptosis promote Bioniche) Ro-31-7453 (apoptosis promoter, La Roche) Brostallicin (apoptosis promoter, Pharmacia)
Alkylating agents	Cyclophosphamide Busulfan Ifosfamide Melphalan Hexamethylmelamine Thiotepa chloroambucil Dacarbazine Carmustine	Lomustine Procarbazine Altretamine Estramustine phosphate Mechloroethamine Streptozocin Temozolomide Semustine
Platinum agents	Cisplatin Oxaliplatin Spiroplatin Carboxyphthalatoplatinum Tetraplatin Ormiplatin Iproplatin	Carboplatin ZD-0473 (AnorMED) Lobaplatin (Aetema) Satraplatin (Johnson Matthey) BBR-3464 (Hoffmann-La Roche) SM-11355 (Sumitomo) AP-5280 (Access)
Antimetabolites	Azacytidine Gemcitabine Capecitabine 5-fluorouracil Floxuridine	Tomudex Trimetrexate Deoxycoformycin Fludarabine Pentostatin

5

10

15

20

25

30

	2-chlorodesoxyadenosine 6-Mercaptopurine 6-Thioguanine Cytarabine 2-fluorodesoxycytidine Methotrexate Idatrexate	Raltitrexed Hydroxyurea Decitabine (SuperGen) Clofarabine (Bioenvision) Irofulven (MGI Pharrna) DMDC (Hoffmann-La Roche) Ethinylcytidine (Taiho)
Topoisomerase inhibitors	Amsacrine Epirubicin Etoposide Teniposide or mitoxantrone Irinotecan (CPT-11) 7-Ethyl-10- hydroxycamptothecin Topotecan Dexrazoxanet (TopoTarget) Pixantrone (Novuspharrna) Rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharrna)	Rubitecan (SuperGen) Exatecan mesylate (Daiichi) Quinamed (ChemGenex) Gimatecan (Sigma- Tau) Diflomotecan (Beaufour- Ipsen) TAS-103 (Taiho) Elsamitrucin (Spectrum) J-107088 (Merck & Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun Dang) KW-2170 (Kyowa Hakko)
Antitumour antibiotics	Dactinomycin (Actinomycin D) Doxorubicin (Adriamycin) Deoxyrubicin Valrubicin Daunorubicin (Daunomycin) Epirubicin Therarubicin Idarubicin Rubidazone Plicamycinp Porfiromycin Cyanomorpholinodoxorubici Mitoxantrone (Novantrone)	Amonafide Azonafide Anthrapyrazole Oxantrazole Losoxantrone Bleomycin sulfate (Blenoxar) Bleomycinic acid Bleomycin A Bleomycin B Mitomycin C MEN-10755 (Menarini) GPX-100 (Gem Pharmaceuticals)

35

5

10

15

20

25

30

35

Antimitotic agents	Paclitaxel	SB 408075
	Docetaxel	(GlaxoSmithKline)
	Colchicine	E7010 (Abbott)
	Vinblastine	PG-TXL (Cell Therapeutics)
	Vincristine	IDN 5109 (Bayer)
	Vinorelbine	A 105972 (Abbott)
	Vindesine	A 204197 (Abbott)
	Dolastatin 10 (NCI)	LU 223651 (BASF)
	Rhizoxin (Fujisawa)	D 24851 (ASTA Medica)
	Mivobulin (Warner-Lambert)	ER-86526 (Eisai)
	Cemadotin (BASF)	Combretastatin A4 (BMS)
	RPR 109881A (Aventis)	Isohomohalichondrin-B
	TXD 258 (Aventis)	(PharmaMar)
	Epothilone B (Novartis)	ZD 6126 (AstraZeneca)
	T 900607 (Tularik)	PEG-Paclitaxel (Enzon)
	T 138067 (Tularik)	AZ10992 (Asahi)
	Cryptophycin 52 (Eli Lilly)	IDN-5109 (Indena)
	Vinflunine (Fabre)	AVLB (Prescient
	Auristatin PE (Teikoku hormone)	NeuroPharma)
	BMS 247550 (BMS)	Azaepothilon B (BMS)
	BMS 184476 (BMS)	BNP- 7787 (BioNumerik)
	BMS 188797 (BMS)	CA-4-prodrug (OXiGENE)
	Taxoprexin (Protarga)	Dolastatin-10 (NrH)
		CA-4 (OXiGENE)
Aromatase inhibitors	Aminoglutethimide	Exemestan
	Letrozole	Atamestan (BioMedicines)
	Anastrozole	YM-511 (Yamanouchi)
	Formestan	
Thymidylate synthase inhibitors	Pemetrexed (Eli Lilly)	Nolatrexed (Eximias)
	ZD-9331 (BTG)	CoFactor™ (BioKeys)
DNA antagonists	Trabectedin (PharmaMar)	Mafosfamide (Baxter International)
	Glufosfamide (Baxter International)	Apaziquone (Spectrum Pharmaceuticals)
	Albumin + 32P (Isotope Solutions)	O6-benzylguanine
	Thymectacin (NewBiotics)	(Paligent)
	Edotreotid (Novartis)	
Farnesyl transferase inhibitors	Arglabin (NuOncology Labs)	Tipifarnib (Johnson & Johnson)
	Ionaafarnib (Schering-Plough)	
	BAY-43-9006 (Bayer)	Perillyl alcohol (DOR BioPharma)
Pump inhibitors	CBT-1 (CBA Pharma)	Zosuquidar trihydrochloride

	Tariquidar (Xenova) MS-209 (Schering AG)	(Eli Lilly) Biricodar dicitrate (Vertex)
5	Histone acetyl transferase in- hibitors	Tacedinaline (Pfizer) SAHA (Aton Pharma) MS-275 (Schering AG) Pivaloyloxymethyl butyrate (Titan) Depsipeptide (Fujisawa)
10	Metalloproteinase inhibitors Ribonucleoside reductase inhibi- tors	Neovastat (Aeterna Labo- ratories) Marimastat (British Biotech) Gallium maltolate (Titan) Triapin (Vion) CMT -3 (CollaGenex) BMS-275291 (Celltech) Tezacitabine (Aventis) Didox (Molecules for Health)
	TNF-alpha agonists/ antagonists	Virulizin (Lorus Therapeutics) Revimid (Celgene) CDC-394 (Celgene)
15	Endothelin-A receptor antagonists	Atrasentan (Abbot) ZD-4054 (AstraZeneca) YM-598 (Yamanouchi)
20	Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson) LGD-1550 (Ligand) Alitretinoin (Ligand)
25	Immunomodulators	Interferon Oncophage (Antigenics) GMK (Progenics) Adenocarcinoma vaccine (Biomira) CTP-37 (AVI BioPharma) JRX-2 (Immuno-Rx) PEP-005 (Peplin Biotech) Synchrovax vaccines (CTL Immuno) Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVax) Dexosome therapy (Anosys) Pentrix (Australian Cancer Technology) JSF-154 (Tragen) Cancer vaccine (Intercell) Norelin (Biostar) BLP-25 (Biomira) MGV (Progenics) 13-Alethin (Dovetail) CLL-Thera (Vasogen)
30		
35	Hormonal and antihormonal agents	Oestrogens Conjugated oestrogens Ethinylloestradiol chlorotrianisene Idenestrol Hydroxyprogesterone capro. Medroxyprogesterone Testosterone Prednisone Methylprednisolone Prednisolone Aminoglutethimide Leuprolide Goserelin Leuporelin Bicalutamide

5

10

15

20

25

30

35

	Testosterone propionate Fluoxymesterone Methyltestosterone Diethylstilbestrol Megestrol Tamoxifen Toremofin Dexamethasone	Flutamide Octreotide Nilutamide Mitotan P-04 (Novogen) 2-Methoxyoestradiol (EntreMed) Arzoxifen (Eli Lilly)
Photodynamic agents	Talaporfin (Light Sciences) Theralux (Theratechnologies) Motexafin gadolinium (Pharmacyclics)	Pd-bacteriopheophorbide (Yeda) Lutetium texaphyrin (Pharmacyclics) Hypericin
Tyrosine kinase inhibitors	Imatinib (Novartis) Leflunomide (Sugen/ Pharmacia) ZD1839 (AstraZeneca) Erlotinib (Oncogene Sciences) Canertinib (Pfizer) Squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia) ZD4190 (AstraZeneca) ZD6474 (AstraZeneca) Vatalanib (Novartis) PKI166 (Novartis) GW2016 (GlaxoSmithKline) EKB-509 (Wyeth) EKB-569 (Wyeth)	Kahalide F (PharmaMar) CEP- 701 (Cephalon) CEP-751 (Cephalon) MLN518 (Millenium) PKC412 (Novartis) Phenoxodiol O Trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech) MDX-H210 (Medarex) 2C4 (Genentech) MDX-447 (Medarex) ABX-EGF (Abgenix) IMC-1C11 (ImClone)
Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP agonist, Ribapharm) Alvocidib (CDK inhibitor, Aventis) CV-247 (COX-2 inhibitor, Ivy Medical) P54 (COX-2 inhibitor, Phytopharm) CapCell™ (CYP450 stimulant, Bavarian Nordic) GCS-100 (gal3 antagonist, GlycoGenesys) G17DT immunogen	BCX-1777 (PNP inhibitor, BioCryst) Ranpirnase (ribonuclease stimulant, Alfacell) Galarubicin (RNA synthesis inhibitor, Dong-A) Tirapazamine (reducing agent, SRI International) N-Acetylcysteine (reducing agent, Zambon) R-Flurbiprofen (NF-kappaB inhibitor, Encore) 3CPA (NF-kappaB inhibitor, Active Biotech)

5

10

15

20

25

30

35

(gastrin inhibitor, Aphton)	Seocalcitol (vitamin D receptor agonist, Leo)
Efaproxiral (oxygenator, Allos Therapeutics)	131-I-TM-601 (DNA antagonist, TransMolecular)
PI-88 (heparanase inhibitor, Progen)	Eflornithin (ODC inhibitor, ILEX Oncology)
Tesmilifen (histamine antagonist, YM BioSciences)	Minodronic acid (osteoclast inhibitor, Yamanouchi)
Histamine (histamine H2 receptor agonist, Maxim)	Indisulam (p53 stimulant, Eisai)
Tiazofurin (IMPDH inhibitor, Ribapharm)	Aplidin (PPT inhibitor, PharmaMar)
Cilengitide (integrin antagonist, Merck KGaA)	Rituximab (CD20 antibody, Genentech)
SR-31747 (IL-1 antagonist, Sanofi-Synthelabo)	Gemtuzumab (CD33 antibody, Wyeth Ayerst)
CCI-779 (mTOR kinase inhibitor, Wyeth)	PG2 (haematopoiesis promoter, Pharmagenesis)
Exisulind (PDE-V inhibitor, Cell Pathways)	Immunol™ (triclosan mouthwash, Endo)
CP-461 (PDE-V inhibitor, Cell Pathways)	Triacetyluridine (uridine prodrug, Wellstat)
AG-2037 (GART inhibitor, Pfizer)	SN-4071 (sarcoma agent, Signature BioScience)
WX-UK1 (plasminogen activator-inhibitor, Willex)	TransMID-107™ (immunotoxin, KS Biomedix)
PBI-1402 (PMN stimulant, ProMetic LifeSciences)	PCK-3145 (apoptosis promoter, Procyon)
Bortezomib (proteasome inhibitor, Millennium)	Doranidazole (apoptosis promoter, Pola)
SRL-172 (T-cell stimulant, SR Pharma)	CHS-828 (cytotoxic agent, Leo)
TLK-286 (glutathione-S transferase inhibitor, Telik)	trans-Retinoic acid (differentiator, NIH)
PT-100 (growth factor agonist, Point Therapeutics)	MX6 (apoptosis promoter, MAXIA)
Midostaurin (PKC inhibitor, Novartis)	Apomine (apoptosis promoter, ILEX Oncology)
Bryostatin-1 (PKC stimulant, GPC Biotech)	Urocidin (apoptosis promoter, Bioniche)
CDA-II (apoptosis promoter, Everlife)	Ro-31-7453 (apoptosis promoter, La Roche)
SDX-101 (apoptosis promoter, Salmedix)	Brostallicin (apoptosis promoter, Pharmacia)
Ceflatonin (apoptosis promoter, ChemGenex)	

The compounds of the formula I are preferably combined with the with known anti-cancer agents:

These known anti-cancer agents include the following: oestrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors and other angiogenesis inhibitors. The present compounds are particularly suitable for administration at the same time as radiotherapy. The synergistic effects of inhibition of VEGF in combination with radiotherapy have been described in the art (see WO 00/61186).

"Oestrogen receptor modulators" refers to compounds which interfere with or inhibit the binding of oestrogen to the receptor, regardless of mechanism. Examples of oestrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl 2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646.

"Androgen receptor modulators" refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate.

"Retinoid receptor modulators" refers to compounds which interfere with or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α -difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl)retinamide and N-4-carboxyphenylretinamide.

"Cytotoxic agents" refers to compounds which result in cell death primarily through direct action on the cellular function or inhibit or interfere with cell myosis, including alkylating agents, tumour necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors.

Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, proflomycin, cisplatin, irofulven, dexifosfamide, cisaminedichloro(2-methylpyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)bis-mu-(hexane-1,6-diamine)mu-[diamineplatinum(II)]bis[diamine(chloro)platinum(II)] tetrachloride, diarisdinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplastone, 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulfonyldaunorubicin (see WO 00/50032).

Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exobenzylidenechartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrzolo[3,4,5-kl]acridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350,

BNP11100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxyetoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a,5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one and dimesna.

"Antiproliferative agents" include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and anti-metabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine, ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tia-zofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-mannoheptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b]-1,4-thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino-furanosyl cytosine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. "Antiproliferative agents" also include monoclonal antibodies to growth factors other than those listed under "angiogenesis inhibitors", such as trastuzumab, and tumour suppressor genes, such as p53, which can be

delivered via recombinant virus-mediated gene transfer (see US Patent No. 6,069,134, for example).

5 Particular preference is given to the use of the compound according to the invention for the treatment and prophylaxis of tumour diseases.

10 The tumour is preferably selected from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.

15 The tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, ovarian carcinoma, glioblastomas, colon carcinoma and breast carcinoma.

20 Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

25

30

35

In another aspect, the invention encompasses a for the treatment of a patient who has a neoplasm, such as a cancer, by administration of a compound of the formula (I) in combination with an antiproliferative agent. Suitable antiproliferative agents encompass those provided in Table 1.

Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means: if necessary, water is added, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. Rt values are determined by HPLC using eluents mentioned.

Mass spectrometry (MS): EI (electron impact ionisation) M^+

FAB (fast atom bombardment) $(M+H)^+$

ESI (electrospray ionisation) $(M+H)^+$

APCI-MS (atmospheric pressure chemical ionisation – mass spectrometry) $(M+H)^+$

(A) HPLC method (non-polar)

Solvent A: water + 0.1% of TFA

Solvent B: acetonitrile+ 0.08% of TFA

Flow: 1.5 ml/min

Gradient: 0.0 min 20% of B

5.0 min 100% of B

5.5 min 100% of B

6.0 min 20% of B

6.5 min 20% of B

Column: Chromolith Performance RP18e 100-3

(B) HPLC/MS method (polar)

Solvent A: water + 0.05% of formic acid

Solvent B: acetonitrile + 0.04% of formic acid

Flow: 2.4 ml/min, wavelength : 220nm

Gradient: 0.0 min 4% of B
2.8 min 100% of B
3.3 min 100% of B
3.4 min 4% of B

Column: Chromolith® Speed ROD RP-18e 50-4.6 mm

(C) HPLC method

Column: Chromolith SpeedROD, 50 x 4.6 mm² (OrderNo. 1.51450.0001)
from Merck

Gradient: 5.0 min, t = 0 min, A:B = 95:5, t = 4.4 min: A:B = 25:75,
t = 4.5 min to t = 5.0 min: A:B = 0:100

Flow: 3.00 ml/min


Eluent A: water + 0.01% of HCOOH (formic acid)

Eluent B: acetonitrile + 0.01% of HCOOH

Wavelength: 220 nm

Example 1

Preparation of 3,5-dichlorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)amino]-ethyl}piperazine-1-carboxylate (**5**)



1.1 0.14 g (0.61 mmol) of **1**, 0.12 g (0.74 mmol) of **2** and 0.2 ml of 4-methylmorpholine are dissolved in 6 ml of DMF. 0.14g (0.73 mmol) of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide x HCl (DAPECI) and 0.1 g (0.74 mmol) of 1-hydroxybenzotriazole (HOBt) are then added. The mixture is stirred at RT for 18 h. The solvent is removed in a rotary evaporator, diluted with water (100 ml) and extracted 2x with EA. The organic phase is dried over magnesium sulfate, filtered off and evaporated to dryness, giving 0.21 g (92.3%) of **3** as brown crystals.


1.2 0.21 g (0.56 mmol) of **3** are dissolved in 20 ml of 5N HCl/isopropanol and stirred at RT for 2h. In order to precipitate the product out completely, 20 ml of ether are added to the batch. The product is filtered off with suction and dried at 45°C in a vacuum drying cabinet, giving 157 mg (80%) of brown crystals.

1.3 50 mg (0.28 mmol) of 3,5-dichlorobenzyl alcohol and 60 mg (0.37 mmol) of 1,1'-carbonyldiimidazole (CDI) are dissolved in 2 ml of DMF

and stirred at RT for 3 h. 0.1 g (0.32 mmol) of **4** are then added and stirred at RT for 18 h. The mixture is washed with water. The organic phase is then dried over sodium sulfate, filtered off, and the solvent is evaporated in vacuo. The residue is purified by means of preparative HPLC, giving 62 mg (46%) of **5** as pale-brown crystals.

Example 2

Preparation of 3,5-dichlorobenzyl 4-[[[2-oxo-2,3-dihydrobenzoxazol-6-yl-carbamoyl)methyl]amino]piperidine-1-carboxylate (**11**)



2.1 169.0 g (1.13 mol) of **9** and 470 ml of triethylamine (3.39 mol) are initially introduced in 2 l of methylene chloride (CH_2Cl_2). A solution of 128 g (1.13 mol) of chloroacetyl chloride in 1l of CH_2Cl_2 is added with ice-cooling at such a rate that an internal temperature of 8°C is not exceeded. The mixture is then boiled under reflux for 20 h. After the reaction mixture has been

cooled, it is stirred with 3 l of water, during which a precipitate forms. The precipitate is filtered off with suction and washed with water and a little methanol, giving 183 g (71.7%) of **10** as amorphous solid substance.

2.2 0.5 g (2.8 mmol) of 3,5-dichlorobenzyl alcohol and 0.55 g (3.4 mmol) of 1,1' carbonyldiimidazole (CDI) are dissolved in 10 ml of CH₂Cl₂ and stirred at RT for 3 h. 0.56 g (2.8 mmol) of **6** are then added and stirred at RT for 18 h. The mixture is washed with water. The organic phase is then dried over sodium sulfate, filtered off, and the solvent is evaporated in vacuo. The residue is purified by means of preparative HPLC, giving 1.0 g (88%) of **7** as white crystals.



2.3 1.0 g (2.48 mmol) of **7** are dissolved in 100 ml of 5N HCl/isopropanol and stirred at RT for 2h. In order to precipitate the product out completely, 200 ml of ether are added to the batch. The product is filtered off with suction and dried at 45°C in a vacuum drying cabinet, giving 0.81 g (96%) of white crystals **8**.

2.4 0.92 g (2.44 mmol) of **8** and 0.54 ml (3.9 mmol) of NEt₃ are initially introduced in 10 ml of DMF, then 0.56 g (2.44 mmol) of **10** are added. The mixture is stirred at RT for 48 h. 30 ml of water were added to the reaction mixture, the crystals which had precipitated out were filtered off with suction. Separation by column chromatography with CH₂Cl₂/MeOH gives 0.26 g (21%) of **11** as brown crystals;
RT [min] 3.68 (method A).

Example 3

Preparation of 3,5-dichlorobenzyl 4-[3-hydroxy-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propyl]piperazine-1-carboxylate (**13**)



51



0.1 g of **12** (0.21 mmol) are dissolved in 5 ml of ethanol, then 30.0 mg (0.79 mmol) of sodium borohydride are added. The mixture is stirred at RT for 14 h. The solvent is then evaporated in vacuo, and the residue is purified by means of preparative HPLC, giving 66 mg (65%) of **13** as yellowish solid substance; RT [min] 3.57 (method A).

Example 4

Preparation of 4-chlorobenzyl 4-[(Z)-3-chloro-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)allyl]piperazine-1-carboxylate (**15**)




35

0.1 g of **14** (0.23 mmol) are mixed with 0.3 g (1.2 mmol) of 1,2-phenylene-dioxytrichlorophosphorane and heated at 100°C for 2 h. 5 ml of methanol are added to the dark-brown melt, and the mixture is treated in an ultrasound bath for 20 min, during which a pale-yellow solid substance precipitates out. This is filtered off with suction and, after drying at 45°C in a drying cabinet, purified by means of preparative HPLC, giving 5.8 mg (6%) of **15** as yellowish solid substance; RT [min] 3.57 (method A).

Example 5

Preparation of 4-chlorobenzyl 4-[3,3-difluoro-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propyl]piperazine-1-carboxylate (**17**)




5.1 3.1 g (7.0 mmol) of **14** are dissolved in 2 ml of glacial acetic acid and 30 ml of DCM. With exclusion of air, 1.3 ml (15 mmol) of ethanedithiol are added, 0.98 ml (7 mmol) of boron trifluoride/acetic acid complex is subsequently added dropwise with exclusion of air. The mixture is stirred at RT for 72 h, and 50 ml of NaHCO₃ solution are then added. The crystals which have precipitated out are filtered off with suction. This is starting material. The organic phase is separated off, dried using MgSO₄. The organic phase is separated off, dried using MgSO₄ and evaporated in vacuo. Purification by

column chromatography on silica gel with ethyl acetate gives 0.1 g (3%) of **16** as amorphous solid substance.

5.2 57 mg (0.2 mmol) of 1,3-dibromo-5,5-dimethylhydantoin are initially introduced in 3 ml of dichloromethane. 0.23 ml (4 mmol) of pyridine/hydrogen fluoride is added at -78°C with exclusion of air. 100 mg (0.19 mmol) of **16**, suspended in 5 ml of dichloromethane, are then added. Stirring is continued for 20 min. The cooling is then removed, and 15 ml of NaHCO₃ solution are added to the reaction mixture. The organic phase is separated off, dried using MgSO₄ and evaporated in vacuo. Purification by means of preparative HPLC gives 15 mg (17%) of **17** as solid substance; RT [min] 2.96 (method C).

Example 6

Preparation of 3,5-dichlorobenzyl 4-{2-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydropyrazol-1-yl]ethyl}piperazine-1-carboxylate (**21**)



6.1 10.0 g (44 mmol) of **18** are dissolved in 100 ml of ethanol. 4.0 g (52 mmol) of hydroxyethylhydrazine and subsequently 7.0 ml (53 mmol) of triethylamine are then added. The mixture is stirred at RT for 2 h. The resul-


tant yellow precipitate is filtered off with suction and dried at 45°C in a vacuum drying cabinet, giving 4.1 g (37.4%) of **19** as yellow crystals.

6.2 0.5 g (2.0 mmol) of **19** are dissolved in 10 ml of DMF. 0.5 ml (6.9 mmol) of thionyl chloride is then added, and the mixture is stirred at RT for 30 min. The reaction mixture is evaporated in vacuo. The residue is triturated with 10 ml of acetonitrile, the crystals are filtered off with suction and dried in air, giving 0.32 g (60%) of **20** as greenish crystals.

6.3 0.12 g (0.4 mmol) of **20**, 0.13 g (0.4 mmol) of 3,5-dichlorobenzyl piperazine-1-carboxylate and 0.1 g (1.2 mmol) of NaHCO₃ are stirred at 100°C for 16 h in 3 ml of acetonitrile. After cooling, 20 ml of water are added to the reaction mixture, which is then extracted twice with CH₂Cl₂. The organic phase is dried using NaSO₄ and evaporated in vacuo. Purification by column chromatography on silica gel with ethyl acetate/methanol gives 21 mg (10%) of **21** as yellow-brown crystals; RT [min] 2.80 (method A).

Example 7

Preparation of 4-chlorobenzyl 4-(2-1H-benzotriazol-5-ylacetyl)piperazine-1-carboxylate (**24**)



7.1 5.0 g (26 mmol) of ethyl 3,4-diaminophenylacetate are dissolved in 40 ml of 50% acetic acid and cooled in an ice bath. 2.7 g (39 mmol) of sodium nitrite in 20 ml of water are added dropwise at such a rate that the temperature remains below 10°C. The mixture is stirred at 10° - 20°C for 3 h. The batch is then diluted with 200 ml of ethyl acetate and washed with water. The organic phase is dried using NaSO₄ and evaporated in vacuo, giving 5.7 g (108%) of **22** as brown oil (also contains a little solvent).

7.2 5.7 g (28 mmol) of **22** are dissolved in 25 ml of water and 10 ml of EtOH, and 75 ml of 5% aqueous NaOH solution are added. The mixture is heated under reflux for 3 h. After cooling, the mixture is evaporated in vacuo. The residue is dissolved in 100 ml of water and adjusted to pH 4 using 5-6 N HCl in propanol. The crystals which have precipitated out are filtered off with suction, giving 3.3 g (56%) of **23** as brown crystals.


7.3 220 mg (1.24 mmol) of **23**, 362 mg (1.24 mmol) of 4-chlorobenzyl piperazine-1-carboxylate hydrochloride, 168 mg (1.24 mmol) of 1-hydroxybenzotriazole (HOBt), 143 mg (1.24 mmol) of N-methylmorpholine and 238 mg (1.24 mmol) of 3-dimethylaminopropylcarbodiimide hydrochloride (DAPECI) are stirred at RT for 48 h in 10 ml of DMF.

The reaction mixture is then evaporated in vacuo. Purification by means of preparative HPLC gives 16 mg (3%) of **24** as colourless solid substance; RT [min] 3.73 (method A);

¹H-NMR (DMSO-d₆) δ [ppm] 7.86 (d, J = 8.5, 1H), 7.75 (d, J = 1.4, 1H), 7.46-7.36 (m, 4H), 7.34 (dd, J = 8.5, 1.4, 1H), 5.10 (s, 2H), 3.95 (s, 2H), 3.65-3.30 (m, 7H).

Example 8

Preparation of 6-(2-{4-[3-(4-chlorophenoxy)propionyl]piperazin-1-yl}acetyl)-3H-benzoxazol-2-one (**27**)



8.1 500 mg (2.5 mmol) of 3-(4-chlorophenoxy)propionic acid, 464 mg (2.5 mmol) of Boc-piperazine and 253 mg (2.5 mmol) of 4-methylmorpholine are initially introduced in 3 ml of DMF. 478 mg (2.5 mmol) of DAPECI and 337 mg (2.5 mmol) of HOBt are then added, and the mixture is stirred at RT for 16 h. The reaction mixture is poured onto water, and the resultant precipitate is filtered off with suction and dried, giving 894 mg (97%) of **25**.

8.2 894 mg (2.4 mmol) of **25** are introduced into 10 ml of 5-6N HCl in propanol and stirred at RT for 0.5 h. The resultant precipitate is filtered off with suction and dried giving 661 mg (89%) of **26**.

8.3 104 mg (0.49 mmol) of 6-(2-chloroacetyl)-3H-benzoxazolone (synthesis described under file reference 102007047737.8 at the German Patent Office) are initially introduced in 3 ml of acetonitrile. 150 mg (1.5 mmol) of triethylamine and 150 mg (0.49 mmol) of **26** are then added, and the mixture is stirred at RT for 16 h and at 80°C for a further 16 h. The resultant precipitate is filtered off, and the filtrate is evaporated in vacuo. Purification by column chromatography on silica gel with EA gives 6 mg (3%) of **27**; RT [min] 3.04 (method A);


$^1\text{H-NMR}$ (DMSO-d_6) δ [ppm] 11.66 (s, 1H), 7.90-7.84 (m, 2H), 7.31 (d, $J = 9.0$, 2H), 7.19 (d, $J = 7.6$, 1H), 6.95 (d, $J = 9.0$, 2H), 4.18 (t, $J = 6.2$, 2H), 3.86 (s, 2H), 3.62 – 3.30 (m, 8H), 2.80 (t, $J = 6.2$, 2H).

5

Example 9

Preparation of 4-chlorobenzyl 4-[2-(1H-benzotriazol-5-ylcarbamoyl)ethylcarbamoyl]piperidine-1-carboxylate (**32**)

10



15

20

25

30

35

9.1 2.7 g (20 mmol) of 5-aminobenzotriazole, 3.8 g (20 mmol) of 3-tert-butoxycarbonylaminopropionic acid, 3.5 g of HOBt (26 mmol) and 4.2 g (22 mmol) of DAPECI are dissolved in 30 ml of DMF and stirred at RT for 16 h. The reaction mixture is then evaporated in vacuo. The residue is taken up in 200 ml of ethyl acetate and washed by shaking twice with water. The organic phase is dried using MgSO_4 and evaporated in vacuo. Purification by

column chromatography on silica gel with ethyl acetate gives 5.7 g (93%) of **28**.

5

9.2 5.7 g (19 mmol) of **28** are dissolved in 60 ml of 6N HCl in isopropanol and stirred at RT for 1h. The reaction mixture is then evaporated in vacuo. The residue is triturated with methylene chloride and filtered off with suction, giving 4.1 g (91%) of **29** as pale-brown amorphous solid substance.

10

9.3 0.97 g (4.0 mmol) of **29**, 0.92 g (4.0 mmol) of 1-butoxycarbonyl-piperidine-4-carboxylic acid, 0.54 g of HOBt (4.0 mmol) and 0.77 g (4.0 mmol) of DAPECI and 0.55 ml of triethylamine (4.0 mmol) are dissolved in 10 ml of DMF and stirred at RT for 16 h. The reaction mixture is then evaporated in vacuo. The residue is taken up in 100 ml of ethyl acetate and washed by shaking twice with water. The organic phase is dried using MgSO₄ and evaporated in vacuo. Purification by column chromatography on silica gel with ethyl acetate gives 1.4 g (84%) of **30**.

15

20

9.4 1.4 g (3.4 mmol) of **30** are dissolved in 20 ml of 6 N HCl in isopropanol and stirred at RT for 1h. The reaction mixture is then evaporated in vacuo, giving 1.1 g (93%) of **31** as brown amorphous solid substance.

25


9.5 81 mg (0.5 mmol) of CDI and 78 mg (0.5 mmol) of 4-chlorobenzyl alcohol are dissolved in 3 ml of DMF and stirred at RT for 2 h. 176 mg (0.5 mmol) of **31** are then added, and the mixture is stirred at RT for 16 h. The reaction mixture is then evaporated in vacuo. The residue is taken up in 20 ml of ethyl acetate and washed by shaking twice with water. The organic phase is dried using MgSO₄ and evaporated in vacuo. The residue is crystallised using ethanol, giving 77 mg (32%) of **32** as pale-brown crystals; RT [min] 3.36 (method C).

30

35

Example 10


Preparation of 4-chlorobenzyl 4-[2-(1H-benzotriazol-5-ylcarbamoyl)ethylcarbamoyl]piperazine-1-carboxylate (**33**)



121 mg (0.5 mmol) of **29** are initially introduced in 3 ml of DMF with 0.035 ml of triethylamine, and 81 mg (0.5 mmol) of CDI are added. The mixture is stirred at RT for 1 h, and 146 mg (0.5 mmol) of 4-chlorobenzyl piperazine-1-carboxylate hydrochloride and a further 0.035 ml of triethylamine are then added. The mixture is then stirred at RT for 2 h. The reaction mixture is then evaporated in vacuo. The residue is taken up in 20 ml of ethyl acetate and washed by shaking twice with water. The organic phase is dried using MgSO_4 and evaporated in vacuo. The residue is recrystallised from ethanol, giving 81 mg (33%) of **33** as pale-brown crystals; RT [min] 3.25 (method C).

Example 11

Preparation of 4-chlorobenzyl 4-[2-(1H-benzotriazol-5-ylcarbamoyl)acetylaminopiperidine-1-carboxylate (**39**)



11.1 5.23 g (27.5 mmol) of **34** and 3.8 ml (27.5 mmol) of triethylamine are initially introduced in 50 ml of methylene chloride. 4.14 g (27.5 mmol) of ethyl malonate chloride are added dropwise with ice-cooling, and the mixture is then stirred at RT for a further 1 h. The reaction mixture is extracted with water, the organic phase is then separated off, dried using NaSO₄ and evaporated in vacuo. Purification by column chromatography on silica gel with ethyl acetate gives 2.85 (34%) of **35** as colourless crystals.

11.2 2.0 g (6.6 mmol) of **35** are dissolved in 20 ml of THF and 20 ml of glacial acetic acid, 2g of 5% Pd/C are added, and the mixture is hydrogenated. The catalyst is filtered off. 6N HCl is added, and the solvent is then evaporated in vacuo, giving 1.6g (97%) of **36** as solid substance.

11.3 1.5 g (10.5 mmol) of 4-chlorobenzyl alcohol, 1.7 g (10.5 mmol) of CDI are stirred at RT for 2 h in 10 ml of DMF. 1.04 ml (7.5 mmol) of triethylamine and 1.6 g (7.5 mmol) of **36** are then added, and the mixture is stirred at RT for 16 h. The reaction mixture is then added to water. The resultant precipitate is filtered off with suction and purified by column chromatography on silica gel


with petroleum ether/ethyl acetate (1:1), giving 1.46 g (51%) of **37** as pale-yellow crystals.





11.4 1.46 g (3.8 mmol) of **37** are dissolved in 10 ml of ethanol, 3.0 ml of aqueous 2N NaOH are added, and the mixture is stirred at RT for 16 h. The solution is acidified using 1N HCl and evaporated in a rotary evaporator. The residue is taken up using ethyl acetate and washed with water. The organic phase is dried using NaSO₄ and evaporated in a rotary evaporator, giving 0.47 g (35%) of **38** as amorphous solid substance.





11.5 0.47 g (1.32 mmol) of **38**, 0.178 g (1.32 mmol) of 5-aminobenzotriazole, 0.28 g (1.46 mmol) of DAPECl and 0.20 g (1.46 mmol) of HOBt are dissolved in 5 ml of DMF and stirred at RT for 16 h. The reaction mixture is then evaporated in vacuo. The residue is taken up in 20 ml of ethyl acetate and washed by shaking twice with water. The organic phase is dried using MgSO₄ and evaporated in vacuo. A white precipitate precipitates out in the process and is filtered off with suction and dried, giving 0.14 g (22%) of **39** as colourless solid substance; RT [min] 3.33 (method C).






The following compounds are obtained analogously to the above examples



the following compounds



No.	Structure and/or name	RT [min] (method)
"A1"	 3,5-Dichlorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate	3.23 (A)

5	"A2"	 4-Trifluoromethylbenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate	3.28 (A)
10	"A3"	 4-Chloro-2-fluorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate	3.12 (A)
15	¹ H-NMR (DMSO-d ₆) δ [ppm] 8.61 (t, J = 5.6, 1H), 8.44 (s, 1H), 7.94 (s, 2H), 7.58-7.41 (m, 3H), 7.34-7.27 (m, 1H), 5.10 (s, 2H), 3.47-3.39 (m, 6H), 2.53 (t, J = 7.0, 2H), 2.47-2.38 (m, 4H)		
20	"A4"	 4-Chlorobenzyl 4-{2-[(1H-benzimidazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate hydrochloride	2.72 (A)
25	¹ H-NMR (DMSO-d ₆) δ [ppm] 9.75 (s, 1H), 8.37 (d, J = 1.0, 1H), 8.12 (dd, J 8.7, 1.0, 1H), 7.99 (d, J = 8.7, 1H), 7.44 (s, 4H), 5.14 (s, 2H), 4.25-4.10 (n, 2H), 3.73 (t, J = 7.0 Hz, 2H), 3.71 – 3.56 (m, 2H), 3.40-3.1 (m, 6H)		
30	"A5"	 4-Chlorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate	3.15 (A)
35			

5	"A6"	 N-{2-[4-(3,5-Dichlorophenylcarbamoyl)piperazin-1-yl]ethyl}-1H-benzotriazole-5-carboxamide	3.12 (A)
10	"A7"	 3,5-Dichlorobenzyl {2-[4-(1H-benzotriazole-5-carbonyl)piperazin-1-yl]ethyl}carbamate	3.15 (A)
20	¹ H-NMR (DMSO-d ₆) δ [ppm] 8.12 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.56 (d, J = 8.6, 1H), 7.46-7.39 (m, 3H), 5.11 (s, 2H), 3.72-3.20 (m, 12H [identified in there: 3.52 (t, J = 5.8, 2H), 3.32 (t, J = 5.8, 2H)]		
25	"A8"	 4-Chlorobenzyl 4-[(2-oxo-2,3-dihydrobenzoxazol-6-ylcarbamoyl)methyl]piperazine-1-carboxylate	3.25 (B)
30	¹ H-NMR (DMSO-d ₆) δ [ppm] 7.67 (d, J = 1.8, 1H), 7.40 (s, 4H), 7.20 (dd, J = 8.4, 1.9, 2H), 7.06 (d, J = 8.4, 1H), 5.10 (s, 2H), 4.18 (s, 2H), 3.68-3.04 (m, 7H)		
35	"A9"		3.31 (B)

	4-Chlorobenzyl 4-[1-(1H-indazol-5-yl-carbamoyl)ethyl]piperazine-1-carboxylate	
5		3.89 (B)
10	4-Chlorobenzyl 4-[(2-oxo-2,3-dihydrobenzoxazol-6-ylcarbamoyl)phenylmethyl]piperazine-1-carboxylate	
15		3.79 (B)
20		3.41 (A)
25	4-Chlorobenzyl 4-[1-(1H-indazol-5-ylcarbamoyl)-1-methylethyl]piperazine-1-carboxylate	
30		3.28 (B)
35	4-Chlorobenzyl 4-[2-(2-oxo-2,3-dihydrobenzoxazol-6-ylcarbamoyl)ethyl]piperazine-1-carboxylate	
		2.35 (C)

	4-Chlorobenzyl 4-[3-(1H-benzotriazol-5-yl-carbamoyl)propyl]piperazine-1-carboxylate	
"A15"	 3,5-Dichlorobenzyl {1-[2-(1H-benzotriazol-5-yl-carbamoyl)ethyl]pyrrolidin-3-yl}carbamate	3.25 (A)
¹ H-NMR (DMSO-d ₆) δ [ppm]	10.31 (s, 1H), 8.36 (s, 1H), 7.86 (d, J = 8.9, 1H), 7.64 (s, 1H), 7.56 (s, 1H), 7.42 (s, 2H), 7.35 (d, J = 8.9, 1H), 5.02 (s, 2H), 4.05-3.89 (m, 2H), 2.86-2.68 (m, 4H), 2.68-2.56 (m, 2H), 2.47-2.31 (m, 2H), 2.19-2.02 (m, 1H), 1.66-1.56 (m, 1H)	
"A16"	 3,5-Dichlorobenzyl {1-[(1H-benzotriazol-5-yl-carbamoyl)methyl]pyrrolidin-3-yl}carbamate	3.25 (A)
¹ H-NMR (DMSO-d ₆) δ [ppm]	15.52 (s, 1H), 9.97 (s, 1H), 8.35 (s, 1H), 7.90 (s, 1H), 7.70 (d, J = 7.4, 1H), 7.61 – 7.35 (m, 4H), 5.04 (s, 2H), 4.05 (s, 1H), 3.45-3.35 (m, 2H, covered by water), 2.89-2.77 (m, 2H), 2.63-2.53 (m, 2H), 2.22-2.12 (m, 1H), 1.72-1.63 (m, 1H)	

"A17"	 3,5-Dichlorobenzyl (1R,5S)-6-[(3H-benzotriazole-5-carbonyl)amino]-3-azabicyclo[3.1.0]hexane-3-carboxylate	3.92 (A)
	¹H-NMR (DMSO-d₆) δ [ppm] 15.91 (s, 1H), 8.70 (d, J = 3.8, 1H), 8.42 (s, 1H), 7.91 (s, 2H), 7.56 (s, 1H), 7.43 (d, J = 1.6, 2H), 5.07 (d, J = 5.2, 2H), 3.67 (d, J = 10.7, 1H), 3.61 (d, J = 10.7, 1H), 3.54 (dd, J = 10.7, 2.6, 1H), 3.47 (dd, J = 10.7, 2.6, 1H), 2.63 (s, 1H), 1.97-1.82 (m, 2H)	
"A18"	 3,5-Dichlorobenzyl 4-[2-hydroxy-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]piperazine-1-carboxylate	3.49 (A)
	¹H-NMR (DMSO-d₆) δ [ppm] 11.50 (s, 1H), 7.56 (t, J = 1.9, 1H), 7.41 (d, J = 1.9, 2H), 7.24 (d, J = 1.1, 1H), 7.12 (dd, J = 8.0, 1.1, 1H), 7.01 (d, J = 8.0, 1H), 5.09 (d, J = 4.0, 1H), 5.07 (s, 2H), 4.74-4.70 (m, 1H), 3.50-3.30 (m, 8H), 2.49-2.38 (m, 2H)	

Autotaxin inhibition (enzyme test)

Table 1

Compound No.	IC50
"11"	B
"13"	B
"15"	
"17"	B
"21"	C
"24"	C
"27"	C
"32"	
"33"	C
"39"	B
"A1"	B
"A2"	C
"A3"	C
"A4"	
"A5"	
"A6"	
"A7"	
"A8"	C
"A9"	
"A10"	C
"A11"	
"A12"	
"A13"	C
"A14"	C
"A15"	
"A16"	C
"A17"	C
"A18"	C

IC50: <100 nM = A
 100 nM - 1 μ M = B
 > 1 μ M = C

5

10

15

20

25

30

35

Example A: Autotaxin test (enzyme test)

Test description

The autotaxin activity is measured indirectly using Amplex Red reagent. Amplex Red is measured here as fluorogenic indicator for the H_2O_2 formed. In detail, autotaxin converts the substrate lysophosphatidylcholine (LPC) into phosphocholine and lysophosphatidyl acid (LPA). After this reaction, the phosphocholine is reacted with alkaline phosphatase to give inorganic phosphate and choline. In the next step, choline is oxidised by choline oxidase to give betaine, with formation of H_2O_2 . H_2O_2 reacts with Amplex Red reagent in the presence of peroxidase (horseradish peroxidase) in a 1:1 stoichiometry and forms the highly fluorescent resorufin. The fluorescence is measured in a reaction-dependent kinetic mode in order that fluorescent signals from possible other fluorescent substances which are not involved in the reaction can be corrected out.

Test procedure

1.5 μ l of a standard solution or of the test substances (substances with the name A(n)) in individual concentrations dissolved in 20mM Hepes pH 7.2 with a maximum of 7.7% of DMSO are pre-incubated together with 10 μ l (16 ng) of highly purified recombinant autotaxin in a black microtitre plate provided with 384 wells at 22°C for 30 min. The reaction is then initiated by addition of 5 μ l of L- α -lysophosphatidylcholine (LPC), where the final concentration of LPC is 75 μ M. The mixture is incubated at 37°C for 90 min. After the incubation, Amplex Red reagent, peroxidase (horseradish peroxidase) and choline oxidase is added, and the fluorescence is immediately measured at 612 nm with excitation of 485 nm in a "Tecan Ultra multimode"

reader. The activity of autotaxin is calculated indirectly via detection of the H_2O_2 formed.

Material:

5

Microtitre plate: PS microplate, 384 wells, small volume, black Corning, Cat#3677

10

Protein: recombinant autotaxin (Baculovirale Hi5 Expression)

Substrate: L- α -lysophosphatidylcholine (chicken egg)); Avanti Polar Lipids # 830071P

15

Standard: C14 LPA, Avanti Polar Lipids, Cat# 857120P

Detection reagent: Amplex Red reagent; Invitrogen # A12222; dissolved in 1.923 ml of DMSO peroxidase type VI-A (horseradish) from Sigma # P6782; dissolved in 7.45 ml of test buffer, choline oxidase; Sigma # C5896; dissolved in 2.47 ml of test buffer

20

Detection reagent mix: 1:100 dilution of Amplex Red reagent in test buffer

25

Test buffer: 200 mM Tris HCl, Merck, Cat # 1.08219, pH 7.9, 0.1% of BSA, lipid-free, Roche Cat#775835

30

The following examples relate to medicaments:

35

Example B: Injection vials

A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.

Example C: Suppositories

A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

Example D: Solution

A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

Example E: Ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.

Example F: Tablets

5 A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active ingredient.

Example G: Dragees

10 Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

Example H: Capsules

15 2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.

Example I: Ampoules

25 A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.


30

35

Patent Claims

1. Compounds of the formula I

5



10

in which

R^1 denotes H, A, Hal, OR^3 , $\text{N}(\text{R}^3)_2$, $\text{N}=\text{CR}^3\text{N}(\text{R}^3)_2$, SR^3 , NO_2 , CN, COOR^3 , $\text{CON}(\text{R}^3)_2$, NR^3COA , $\text{NR}^3\text{SO}_2\text{A}$, $\text{SO}_2\text{N}(\text{R}^3)_2$, $\text{S}(\text{O})_m\text{A}$, $-\text{C}(\text{R}^3)_2]_n\text{N}(\text{R}^3)_2$, $\text{O}[\text{C}(\text{R}^3)_2]_p\text{N}(\text{R}^3)_2$, $\text{S}[\text{C}(\text{R}^3)_2]_n\text{N}(\text{R}^3)_2$, $-\text{NR}^3[\text{C}(\text{R}^3)_2]_n\text{N}(\text{R}^3)_2$, $\text{NHCON}(\text{R}^3)_2$, $\text{CON}(\text{R}^3)_2$, $\text{CONR}^3[\text{C}(\text{R}^3)_2]_n\text{N}(\text{R}^3)_2$ or COA,

15

R^3 denotes H or A,

X denotes O, NH or CH_2 ,

Y denotes CH_2 , CH_2O or is absent,


20


R denotes

25

30

35





5

10

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one or two CH₂ groups may be replaced by O, NH and/or S,

15

or

cyclic alkyl having 3-7 C atoms,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

m denotes 0, 1 or 2,

20

p denotes 0, 1, 2, 3, 4 or 5,

and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

25

2. Compounds according to Claim 1 in which R¹ denotes Hal, and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

30

3. Compounds according to Claim 1 or 2 in which X denotes O or CH₂, and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

35

4. Compounds according to one or more of Claims 1-3 in which

Y denotes CH₂ or CH₂O,
and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

5

5. Compounds according to one or more of Claims 1-4 in which
A denotes unbranched or branched alkyl having 1-10 C atoms,
in which 1-7 H atoms may be replaced F and/or Cl,
and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

10

6. Compounds according to one or more of Claims 1-5 in which
p denotes 1, 2 or 3,
and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

15


7. Compounds according to one or more of Claims 1-6 in which
R¹ denotes Hal,
X denotes O or CH₂,
Y denotes CH₂ or CH₂O,
R denotes


20

25

30

35

















A denotes unbranched or branched alkyl having 1-10 C atoms,
in which 1-7 H atoms may be replaced F and/or Cl,
Hal denotes F, Cl, Br or I,
p denotes 1, 2 or 3,
and pharmaceutically usable salts and stereoisomers thereof, including
mixtures thereof in all ratios.





8. Compounds according to Claim 1 selected from the group



No.	Name and/or structure
"11"	3,5-Dichlorobenzyl 4-[[2-oxo-2,3-dihydrobenzoxazol-6-yl-carbamoyl)methyl]amino}piperidine-1-carboxylate
"13"	3,5-Dichlorobenzyl 4-[3-hydroxy-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propyl]piperazine-1-carboxylate
"15"	4-Chlorobenzyl 4-[(Z)-3-chloro-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)allyl]piperazine-1-carboxylate
"17"	4-Chlorobenzyl 4-[3,3-difluoro-3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propyl]piperazine-1-carboxylate
"21"	3,5-Dichlorobenzyl 4-{2-[3-(2-oxo-2,3-dihydrobenzoxazol-6-yl)-4,5-dihydropyrazol-1-yl]ethyl}piperazine-1-carboxylate
"24"	4-Chlorobenzyl 4-(2-1H-benzotriazol-5-ylacetyl)piperazine-1-carboxylate

"27"	6-(2-{4-[3-(4-Chlorophenoxy)propionyl]piperazin-1-yl}-acetyl)-3H-benzoxazol-2-one
"32"	4-Chlorobenzyl 4-[2-(1H-benzotriazol-5-yl-carbamoyl)ethyl]carbamoyl]piperidine-1-carboxylate
"33"	4-Chlorobenzyl 4-[2-(1H-benzotriazol-5-ylcarbamoyl)ethyl-carbamoyl]piperazine-1-carboxylate
"39"	4-Chlorobenzyl 4-[2-(1H-benzotriazol-5-ylcarbamoyl)acetyl-amino]piperidine-1-carboxylate
"A1"	 3,5-Dichlorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)-amino]ethyl}piperazine-1-carboxylate
"A2"	 4-Trifluoromethylbenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)-amino]ethyl}piperazine-1-carboxylate
"A3"	 4-Chloro-2-fluorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)-amino]ethyl}piperazine-1-carboxylate

5	"A4"	 4-Chlorobenzyl 4-{2-[(1H-benzimidazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate
10	"A5"	 4-Chlorobenzyl 4-{2-[(1H-benzotriazole-5-carbonyl)amino]ethyl}piperazine-1-carboxylate
15	"A6"	 N-{2-[4-(3,5-Dichlorophenylcarbamoyl)piperazin-1-yl]ethyl}-1H-benzotriazole-5-carboxamide
25	"A7"	 3,5-Dichlorobenzyl {2-[4-(1H-benzotriazole-5-carbonyl)-piperazin-1-yl]ethyl}carbamate


5	"A8"	 4-Chlorobenzyl 4-[(2-oxo-2,3-dihydrobenzoxazol-6-yl-carbamoyl)methyl]piperazine-1-carboxylate
10	"A9"	 4-Chlorobenzyl 4-[1-(1H-indazol-5-ylcarbamoyl)ethyl]piperazine-1-carboxylate
15	"A10"	 4-Chlorobenzyl 4-[(2-oxo-2,3-dihydrobenzoxazol-6-yl-carbamoyl)phenylmethyl]piperazine-1-carboxylate
20	"A11"	 4-Chlorobenzyl 4-[1-(1H-indol-5-ylcarbamoyl)ethyl]piperazine-1-carboxylate
25	"A12"	 4-Chlorobenzyl 4-[1-(1H-indazol-5-ylcarbamoyl)-1-methyl-ethyl]piperazine-1-carboxylate
30		
35		

5	"A13"	 4-Chlorobenzyl 4-[2-(2-oxo-2,3-dihydrobenzoxazol-6-yl-carbamoyl)ethyl]piperazine-1-carboxylate
10	"A14"	 4-Chlorobenzyl 4-[3-(1H-benzotriazol-5-ylcarbamoyl)propyl]-piperazine-1-carboxylate
15	"A15"	 3,5-Dichlorobenzyl {1-[2-(1H-benzotriazol-5-ylcarbamoyl)-ethyl]pyrrolidin-3-yl}carbamate
20	"A16"	 3,5-Dichlorobenzyl {1-[(1H-benzotriazol-5-ylcarbamoyl)-methyl]pyrrolidin-3-yl}carbamate


"A17"	 3,5-Dichlorobenzyl (1R,5S)-6-[(3H-benzotriazole-5-carbonyl)amino]-3-azabicyclo[3.1.0]hexane-3-carboxylate
"A18"	 3,5-Dichlorobenzyl 4-[2-hydroxy-2-(2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl]piperazine-1-carboxylate

and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. Process for the preparation of compounds of the formula I and pharmaceutically usable salts and stereoisomers thereof, characterised in that
- a) for the preparation of compounds of the formula I in which



a compound of the formula II




in which

Het has the meaning indicated in Claim 1,

and L denotes Cl or Br,

is reacted with a compound of the formula III




in which


X, Y, R¹ and p have the meanings indicated in Claim 1,

or

b) for the preparation of compounds of the formula I in which



a compound of the formula IV




in which

Het has the meaning indicated in Claim 1,

and L denotes Cl or Br,

is reacted with a compound of the formula V



5

in which


X, Y, R¹ and p have the meanings indicated in Claim 1,

or

10


c) for the preparation of compounds of the formula I in which

15



a compound of the formula VI

20



in which

Het has the meaning indicated in Claim 1,

and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

25


is reacted with a compound of the formula V,

30


or

d) for the preparation of compounds of the formula I in which

35




a compound of the formula VII



in which

Het has the meaning indicated in Claim 1,

is reacted with a compound of the formula VIII




in which

R^1 and p have the meanings indicated in Claim 1,


and a compound selected from the group
carbonyldiimidazole, phosgene, diphosgene, triphosgene,

or

e) for the preparation of compounds of the formula I in which



a compound of the formula IX




in which

Het has the meaning indicated in Claim 1,


is reacted with a compound of the formula V
and a compound selected from the group
carbonyldiimidazole, phosgene, diphosgene, triphosgene,

or

f) for the preparation of compounds of the formula I in which




a compound of the formula X



in which

Het has the meaning indicated in Claim 1,

is reacted with a compound of the formula XI



in which

X, Y, R¹, p have the meanings indicated in Claim 1,

and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or a base or acid of the formula I is converted into one of its salts.

10. Medicaments comprising at least one compound of the formula I according to Claim 1 to 8 and/or pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
11. Use of compounds according to Claim 1 to 8 for the preparation of a medicament for the treatment and prophylaxis of cancer diseases.
12. Use according to Claim 11, where the cancer diseases are associated with a tumour from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.
13. Use according to Claim 12, where the tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, ovarian carcinoma, glioblastomas and breast carcinoma and colon carcinoma.

14. Use according to Claim 13, where the disease to be treated is a tumour of the blood and immune system.
- 5 15. Use according to Claim 14, where the tumour originates from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
- 10 16. Use of compounds of the formula I according to Claim 1 to 8 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of tumours where a therapeutically effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) other angiogenesis inhibitors.
- 20

25

30

35